Unorganized Prostate-specific Antigen–based Screening for Prostate Cancer: More Harm than Benefit. When Will We Finally Start to Implement Guidelines and Risk Assessment Tools in Clinical Practice?

Roobol, Monique J.

doi:10.1016/j.eururo.2015.02.036

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the one hand, evidence indicates that it reduces PCa mortality, but on the other hand, there is a risk of overdiagnosis and overtreatment. Offering PSA in an organised way and combining it with other relevant risk factors regarding PCa will most likely result in a more beneficial harm-benefit ratio [20][21][22]. Our study confirms that individual risk assessment using a multivariable prediction model should be used in the consideration whether or not to perform PBx.…”

Section: Discussionsupporting

confidence: 71%

Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort

Gayet

Mannaerts

Nieboer

et al. 2018

European Urology Focus

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 71%

Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort

Gayet

Mannaerts

Nieboer

et al. 2018

European Urology Focus

Self Cite

View full text Add to dashboard Cite

“…However, it is crucial that guidelines and readily available risk stratification tools are implemented into daily practice, in order to stop the misuse of the PSA test. [113]…”

Section: Resultsmentioning

confidence: 99%

What's new in screening in 2015?

Carlsson

Roobol

2016

Current Opinion in Urology

Self Cite

View full text Add to dashboard Cite

Purpose of review The aim of this review was to highlight important articles in the field of prostate cancer (PC) screening published during 2015 and early 2016. Four major areas were identified: 1. screening strategies; 2. post USPSTF 2011–2012; 3. screening trends/patterns; and 4. shared decision making (SDM). Recent findings Several studies furthered the evidence that screening reduces the risk of metastasis and death from PC. Multiplex screening strategies are of proven benefit; genetics and MRI need further evaluation. PSA screening rates declined in men above age 50 as did the overall PC incidence following the USPSTF 2011–2012 recommendation against PSA. The consequences of declining screening rates will become apparent in the next few years. More research is needed to identify the most optimal approach to engage in, and implement, effective SDM in clinical practice. Summary Data emerging in 2015 provided evidence on the question of how best to screen and brought more steps in the right direction of “next-generation PC screening”. Screening is ongoing in all men regardless of whether they might benefit from early detection and treatment or not. After the USPSTF 2011–2012 recommendation the rates of PSA testing are declining, however this decline is observed in all men and not solely in those who will not benefit. The long-term effect of this recommendation might not be as anticipated. More studies are needed on how to implement the best available evidence on who, and when, to screen into clinical practice.

show abstract

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy

Mannaerts

Gayet

Verbeek

et al. 2018

European Urology Oncology

View full text Add to dashboard Cite

Unorganized Prostate-specific Antigen–based Screening for Prostate Cancer: More Harm than Benefit. When Will We Finally Start to Implement Guidelines and Risk Assessment Tools in Clinical Practice?

Cited by 4 publications

References 10 publications

Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort

Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort

What's new in screening in 2015?

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy

Contact Info

Product

Resources

About